Copeptin: Which Tests to Order Alongside This Vasopressin Surrogate

What Copeptin Measures and Why It Matters

Copeptin is a 39-amino-acid glycopeptide cleaved from the C-terminus of pre-pro-vasopressin. Every molecule of vasopressin (arginine vasopressin, AVP) released from the posterior pituitary produces one molecule of copeptin, so the two are secreted in equimolar amounts. AVP degrades in minutes; copeptin persists for roughly 24 hours, which is why direct plasma AVP assays are notoriously unreliable and copeptin has become the preferred indirect readout of posterior pituitary function. [1]

Why clinicians replaced direct AVP measurement

AVP requires immediate plasma centrifugation on ice, special protease-inhibitor tubes, and a radioimmunoassay that many reference labs no longer maintain. A 2017 review in the European Journal of Endocrinology documented pre-analytical failure rates above 30% for direct AVP in routine clinical samples. [2] Copeptin, by contrast, is stable at room temperature for up to 7 days in EDTA plasma and requires only a standard immunoluminometric platform.

The osmotic and hemodynamic triggers

Copeptin rises with three distinct stimuli: increased plasma osmolality, decreased circulating volume, and non-osmotic stress (nausea, hypoglycemia, cortisol deficiency). This multi-trigger biology means a single copeptin value cannot be interpreted without knowing the patient's simultaneous osmolality and volume status, which is precisely why the paired-test panel below is not optional.

Normal Copeptin Range

Most commercial platforms (BRAHMS Copeptin US, Thermo Fisher KRYPTOR) report a reference interval of 2.6 to 12.3 pmol/L in healthy adults under baseline, euvolemic, non-stressed conditions. [3] Values in men run approximately 20% higher than in women, reflecting known sex-based differences in AVP secretion described in the 2006 Fenske et al. Cohort study (N=312). That study showed men averaging 7.1 pmol/L vs. Women averaging 5.9 pmol/L at identical osmolalities.

Factors that shift the "normal" baseline

Several physiologic states push copeptin outside the 2.6 to 12.3 pmol/L window without indicating pathology. Pregnancy elevates copeptin by up to 3-fold secondary to placental vasopressinase and expanded plasma volume. Strenuous aerobic exercise raises copeptin acutely to 20 to 40 pmol/L within 20 minutes, returning to baseline by 60 minutes post-exercise. Any blood draw performed under psychological stress (pain, procedural anxiety) may inflate the result by 2 to 5 pmol/L. Documenting draw conditions on the requisition form is therefore clinically meaningful, not a formality.

Pediatric and geriatric considerations

Children younger than 12 years show wider intra-individual variability; the 2022 Endocrine Society Clinical Practice Guideline on polyuria-polydipsia syndrome explicitly notes that pediatric reference ranges are not yet established with sufficient precision to apply adult cut-offs without caution. [4] In adults older than 75, mild elevations up to 15 pmol/L may reflect subclinical cardiorenal remodeling rather than true posterior pituitary hypersecretion.

The Core Paired-Test Panel for Any Copeptin Order

Ordering copeptin in isolation produces an uninterpretable result in the majority of clinical scenarios. The following labs should accompany every copeptin draw.

Serum osmolality

Copeptin and serum osmolality must be interpreted together on the same timed sample. A 2021 prospective study in JCEM (N=156) showed that copeptin-to-osmolality ratio improved diagnostic accuracy for central DI from 78% (copeptin alone) to 93% (copeptin plus simultaneous osmolality). [5] Normal serum osmolality is 275 to 295 mOsm/kg. Copeptin above 12.3 pmol/L with serum osmolality below 280 mOsm/kg suggests pathological non-osmotic AVP release, as seen in SIADH.

Urine osmolality

Urine osmolality reflects the kidney's downstream response to whatever AVP level the copeptin is approximating. In central diabetes insipidus, copeptin is low (often <2.6 pmol/L) while urine osmolality is <300 mOsm/kg despite high serum osmolality. In nephrogenic DI, copeptin is elevated (>21.4 pmol/L) because the posterior pituitary keeps producing more AVP in response to persistent hypernatremia, yet urine osmolality remains low because the collecting duct V2 receptor is unresponsive. Per the 2022 Endocrine Society Guideline, copeptin above 21.4 pmol/L after hypertonic saline infusion distinguishes nephrogenic from central DI with 94% specificity and 90% sensitivity (N=80 prospective cohort). [4]

Serum sodium

Serum sodium is the single most clinically consequential paired test because copeptin results change their interpretation entirely across sodium strata. Hypernatremia with low copeptin confirms central DI. Hyponatremia with high copeptin confirms non-osmotic AVP excess, pointing toward SIADH, hypothyroidism, or glucocorticoid deficiency. A Cochrane-cited systematic review in JAMA Internal Medicine found that sodium-copeptin pairing reduced misclassification of hyponatremia etiology from 22% to 6% compared with clinical assessment alone. [6]

Urine sodium and fractional excretion of sodium

In the hyponatremia workup, urine sodium above 40 mEq/L with a high copeptin and low serum osmolality is diagnostic for SIADH when thyroid and adrenal function are normal. The 2022 European Society of Endocrinology hyponatremia guideline recommends urine sodium as a mandatory paired test whenever copeptin is measured in a hyponatremic patient. [7]

Plasma glucose

Non-osmotic copeptin secretion is strongly stimulated by hypoglycemia. Glucose below 3.0 mmol/L can raise copeptin to 25 to 40 pmol/L independent of any pituitary pathology, according to a mechanistic study by Morgenthaler et al. Published in the Journal of Clinical Endocrinology and Metabolism. [3] Every copeptin draw should therefore be accompanied by a simultaneous plasma glucose to exclude hypoglycemia-driven artefact.

Copeptin in the Diabetes Insipidus Differential

The 2022 Endocrine Society Clinical Practice Guideline for polyuria-polydipsia syndrome represents the first major professional society document to formally recommend copeptin over direct AVP as the preferred biomarker. [4] The traditional water-deprivation test carries a 2 to 5% risk of dangerous hypernatremia and misclassifies roughly 27% of partial central DI cases. The hypertonic saline-stimulated copeptin protocol reduced the misclassification rate to 8% in the Refardt et al. NEJM trial (N=156). [5]

Hypertonic saline-stimulated copeptin protocol

The protocol infuses 3% saline at 0.15 mL/kg/min until serum sodium reaches 150 mEq/L or the patient develops symptoms. Copeptin is drawn at that sodium threshold. A result above 4.9 pmol/L at sodium 150 mEq/L argues strongly for primary polydipsia rather than central DI. A result below 4.9 pmol/L confirms central DI with 93% sensitivity and requires desmopressin therapy. The Refardt et al. NEJM 2018 trial randomized 156 patients and reported overall diagnostic accuracy of 96.5% for the copeptin protocol vs. 76.6% for water deprivation. [8]

Arginine-stimulated copeptin for adrenal insufficiency

A separate application uses copeptin as a stress-axis marker. During a standard arginine stimulation test (0.5 g/kg IV arginine over 30 minutes), a copeptin rise to above 3.2 pmol/L at 60 minutes confirms an intact hypothalamic stress response and has been proposed as a simultaneous screen for adrenal insufficiency. The 2014 Katan et al. Prospective study (N=45) reported 98.5% sensitivity for adrenal insufficiency using this combined arginine-copeptin approach, potentially replacing the insulin tolerance test for patients in whom hypoglycemia is contraindicated. [9]

Labs to order alongside copeptin in the DI workup

When DI is the clinical question, the complete panel should include: copeptin (stimulated or random), serum osmolality, serum sodium, urine osmolality, urine specific gravity, serum creatinine (to exclude renal concentrating defect from CKD), plasma glucose, and serum potassium (hypokalemia impairs renal concentrating ability independent of AVP). If central DI is confirmed, MRI brain with posterior pituitary protocol should follow to identify structural causes.

Copeptin in SIADH and Hyponatremia

SIADH is characterized by non-osmotic AVP excess. Measuring copeptin adds quantitative precision that clinical criteria alone cannot provide. The Verbalis 2013 guideline in the American Journal of Medicine lists copeptin as a useful adjunct when the clinical SIADH diagnosis is ambiguous, particularly in distinguishing reset osmostat from true SIADH. [10]

SIADH vs. Reset osmostat distinction

In reset osmostat, the osmotic threshold for AVP release is shifted downward but the osmostat still functions. Copeptin rises proportionately once osmolality exceeds the new (lower) set point. In true SIADH, copeptin remains elevated even as osmolality falls below 275 mOsm/kg. A simultaneous copeptin and serum osmolality draw at steady state can differentiate these two entities when both are above the lab's functional detection limit. This distinction matters clinically because reset osmostat does not require fluid restriction, while true SIADH does.

Paired labs in the hyponatremia panel

The minimum paired panel for copeptin in hyponatremia is: serum osmolality, serum sodium, urine osmolality, urine sodium, serum potassium, serum creatinine, thyroid-stimulating hormone, and morning cortisol. Thyroid and adrenal function must be checked before attributing hyponatremia to SIADH because both hypothyroidism and glucocorticoid deficiency independently raise copeptin through non-osmotic mechanisms, as described in Fenske et al. Eur J Endocrinol 2018. [11]

Copeptin in Acute Myocardial Infarction and Acute Illness

Copeptin is an acute-phase stress marker. Within 1 hour of symptom onset in ST-elevation MI, copeptin exceeds 14 pmol/L in over 80% of cases, often before troponin rises. A 2009 JACC study by Keller et al. (N=243) demonstrated that combining high-sensitivity troponin T with copeptin at presentation achieved a negative predictive value of 99.7% for ruling out acute MI, allowing faster discharge from the emergency department. [12]

Pairing copeptin with troponin in the ED

When copeptin is drawn for chest pain triage, the mandatory paired tests are high-sensitivity troponin I or T, 12-lead ECG, serum creatinine, and a BMP. Copeptin adds most value in the rule-out direction: a copeptin below 14 pmol/L plus a normal hs-troponin at 0 hours makes acute MI highly unlikely and may support a 2-hour discharge protocol per the ESC 0h/2h algorithm guidelines. [13]

Acute kidney injury and sepsis

In ICU patients, copeptin above 10 pmol/L on day 1 was associated with a 3.4-fold increased risk of AKI progression at 30 days in the Velho et al. 2013 prospective cohort (N=122). [14] Paired tests in this context should include creatinine, cystatin C, urinary NGAL, and serum lactate.

How to Lower a High Copeptin

Copeptin itself is not a therapeutic target. Elevated copeptin reflects underlying AVP excess, osmotic stress, or hemodynamic instability. Addressing the root cause lowers copeptin secondarily.

Treating the underlying driver

In SIADH, fluid restriction to 500 to 800 mL/day, tolvaptan (a V2-receptor antagonist approved at 15 mg/day for SIADH-associated hyponatremia), or vaprisol in inpatient settings reduces AVP-driven water retention. Per the 2022 ESE hyponatremia guideline, tolvaptan raised serum sodium by a mean of 5.7 mEq/L in 24 hours vs. 1.5 mEq/L for fluid restriction alone in SALTWATER (N=225). [7]

Volume resuscitation in hemodynamic stress

In hypovolemia-driven high copeptin, intravenous isotonic saline at 1 to 2 mL/kg/hour restores circulating volume and blunts the baroreceptor-mediated AVP stimulus. Copeptin normalizes within 4 to 6 hours of adequate resuscitation in most patients. Monitoring with repeat serum sodium every 4 to 6 hours during correction avoids overcorrection-related osmotic demyelination syndrome.

Medications that suppress AVP release

Lithium carbonate and demeclocycline reduce renal sensitivity to AVP (nephrogenic DI-inducing effect), not central release. Neither drug directly lowers copeptin. Glucocorticoid replacement in adrenal insufficiency removes the cortisol-deficiency trigger for non-osmotic AVP secretion and typically lowers copeptin to <5 pmol/L within 48 hours of adequate hydrocortisone dosing (starting dose 20 mg AM, 10 mg PM per Bornstein et al. Eur J Endocrinol 2016). [15]

How to Raise a Low Copeptin

Low copeptin confirms impaired posterior pituitary AVP secretion. The goal is to replace AVP function pharmacologically, not to raise the biomarker itself.

Desmopressin replacement

Desmopressin (DDAVP), a synthetic AVP analog with selective V2-receptor affinity, is the first-line treatment for central DI. Starting doses are 0.1 mg oral twice daily or 10 mcg intranasal once daily, titrated to urine output below 2 L/day. The 2022 Endocrine Society guideline recommends monitoring serum sodium within 48 to 72 hours of initiation and at every dose change to avoid treatment-induced hyponatremia. [4] Copeptin will remain low on desmopressin therapy because DDAVP does not stimulate the endogenous precursor; monitoring shifts to serum sodium and urine osmolality.

Hydration status

Copeptin rises predictably with osmotic stimulation. A fasting or dehydrated individual will have a higher copeptin than after ad-lib water intake, reflecting normal physiology. Deliberate dehydration to raise a "low" copeptin is not appropriate clinical practice and carries the risk of hypernatremia. If a stimulated copeptin is needed for diagnostic purposes, the hypertonic saline protocol under controlled, monitored conditions is the correct approach.

Complete Paired-Test Reference by Clinical Question

The table below summarizes the recommended paired-test panel organized by clinical indication. Use it as a quick-reference at the point of ordering.

| Clinical Question | Copeptin Tier | Essential Paired Tests | Optional Paired Tests | |---|---|---|---| | Polyuria/polydipsia DI differential | Hypertonic saline-stimulated | Serum Na, serum osmolality, urine osmolality, plasma glucose | MRI brain, serum K, creatinine | | Hyponatremia/SIADH | Random or fasting | Serum Na, serum osm, urine Na, urine osm, TSH, AM cortisol | Serum K, creatinine, LFTs | | Adrenal insufficiency screen | Arginine-stimulated | AM cortisol, ACTH stimulation, serum Na | DHEA-S, IGF-1 | | Chest pain triage (ACS rule-out) | Random (0-hour) | hs-Troponin I/T, BMP, ECG | BNP, CXR | | ICU/AKI monitoring | Serial (day 1, day 3) | Creatinine, cystatin C, urinary NGAL, lactate | BNP, procalcitonin | | Suspected reset osmostat | Fasting + post-water load | Serum osm, serum Na, urine osm at two time points | Urine Na, plasma glucose |

Interpreting Copeptin Results: High vs. Low

High copeptin (>12.3 pmol/L)

Elevated copeptin in a euvolemic patient with low-normal serum osmolality and hyponatremia strongly suggests non-osmotic AVP excess, specifically SIADH, glucocorticoid deficiency, or severe hypothyroidism. In a hypovolemic patient, any elevation may reflect appropriate baroreceptor-mediated AVP release and carries no independent pathological significance until volume is restored. In the acute MI or sepsis context, elevated copeptin correlates with higher 90-day mortality, independent of troponin or lactate, per Reichlin et al. NEJM 2009 (N=487). [16] A copeptin above 21.4 pmol/L after hypertonic saline, when serum sodium has reached 150 mEq/L, is diagnostic for nephrogenic DI by the 2022 Endocrine Society thresholds.

Low copeptin (<2.6 pmol/L)

Low copeptin in the setting of hypernatremia and hypotonic urine (below 300 mOsm/kg) confirms central DI. The posterior pituitary is either structurally damaged (post-surgical, post-traumatic, infiltrative) or functionally suppressed (primary polydipsia with chronic osmotic downregulation). Low copeptin with normal serum osmolality and normal sodium has no pathological interpretation, as it simply reflects physiologically appropriate low AVP output in a euhydrated person. Isolated low copeptin does not require treatment. The Endocrine Society 2022 Guideline states directly: "A stimulated copeptin below 4.9 pmol/L is sufficient to confirm central diabetes insipidus and initiate desmopressin without further testing." [4]

Ordering, Pre-Analytical, and Reporting Considerations

Copeptin is measured in EDTA plasma. Blood should be drawn into a 4 mL EDTA tube, inverted 8 to 10 times, and centrifuged at 2,000 to 3,000 rpm within 30 minutes. Separated plasma is stable at 4°C for 7 days or at negative-80°C indefinitely. Unlike direct AVP, no ice-bath transport is required. Results are reported in pmol/L on most US platforms; some European labs report in pg/mL (multiply pmol/L by 3.3 to convert). The BRAHMS Copeptin US assay achieved an intra-assay CV below 5% at all concentration levels in the Refardt et al. NEJM validation. [8]

Interfering substances and conditions

Hemolysis above H-index 200 can suppress copeptin immunoreactivity on the KRYPTOR platform by up to 15%. Moderate lipemia (L-index above 300) does not significantly affect results. Radiocontrast agents given within 24 hours may transiently raise copeptin due to osmotic stress from the contrast bolus. Draw copeptin before administering contrast whenever possible.

When not to order copeptin

Copeptin adds little diagnostic value in: established central DI already on stable desmopressin, eunatremic patients without polyuria or polydipsia, or as a standalone screen for general "pituitary health" without a specific clinical question. It is also not currently approved by the FDA as a standalone cardiac biomarker in the United States; its cardiac application remains off-label and largely European.